Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems

被引:35
作者
Ladaviere, Catherine [1 ]
Gref, Ruxandra [2 ]
机构
[1] Univ Lyon 1, INSA Lyon, IMP, UMR CNRS 5223, F-69100 Villeurbanne, France
[2] Univ Paris 11, UMR CNRS 8214, Inst Mol Sci, F-91400 Orsay, France
关键词
antibiotics; bacteria; delivery systems; drug loading; intracellular infections; nanocarrier; nanomedicine; nanoparticle; nanotechnology; phagocytic cells; resistance mechanisms; MYCOBACTERIUM-AVIUM COMPLEX; LIPOSOME-ENCAPSULATED STREPTOMYCIN; LISTERIA-MONOCYTOGENES INFECTION; STERICALLY STABILIZED LIPOSOMES; AMPICILLIN-LOADED NANOPARTICLES; CORE-SHELL NANOSTRUCTURES; RAT ALVEOLAR MACROPHAGES; STAPHYLOCOCCUS-AUREUS; IN-VITRO; CHITOSAN NANOPARTICLES;
D O I
10.2217/nnm.15.128
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Intracellular pathogenic bacteria can lead to some of the most life-threatening infections. By evolving a number of ingenious mechanisms, these bacteria have the ability to invade, colonize and survive in the host cells in active or latent forms over prolonged period of time. A variety of nanoparticulate systems have been developed to optimize the delivery of antibiotics. Main advantages of nanoparticulate systems as compared with free drugs are an efficient drug encapsulation, protection from inactivation, targeting infection sites and the possibility to deliver drugs by overcoming cellular barriers. Nevertheless, despite the great progresses in treating intracellular infections using nanoparticulate carriers, some challenges still remain, such as targeting cellular subcompartments with bacteria and delivering synergistic drug combinations. Engineered nanoparticles should allow controlling drug release both inside cells and within the extracellular space before reaching the target cells.
引用
收藏
页码:3033 / 3055
页数:23
相关论文
共 208 条